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Streptococcus mutans is the primary agent of dental cavities, in large part due to its
ability to adhere to teeth and create a molecular scaffold of glucan polysaccharides on
the tooth surface. Disrupting the architecture of S. mutans biofilms could help undermine
the establishment of biofilm communities that cause cavities and tooth decay. Here we
present a synthetic peptide P1, derived from a tick antifreeze protein, which significantly
reduces S. mutans biofilm formation. Incubating cells with this peptide decreased biofilm
biomass by approximately 75% in both a crystal violet microplate assay and an in vitro
tooth model using saliva-coated hydroxyapatite discs. Bacteria treated with peptide
P1 formed irregular biofilms with disconnected aggregates of cells and exopolymeric
matrix that readily detached from surfaces. Peptide P1 can bind directly to S. mutans
cells but does not possess bactericidal activity. Anti-biofilm activity was correlated
with peptide aggregation and β-sheet formation in solution, and alternative synthetic
peptides of different lengths or charge distribution did not inhibit biofilms. This anti-
biofilm peptide interferes with S. mutans biofilm formation and architecture, and may
have future applications in preventing bacterial buildup on teeth.
Keywords: biofilm, anti-biofilm, synthetic peptide, Streptococcus mutans, Gram-positive cocci, aggregation
INTRODUCTION
The ability of oral streptococci to establish biofilm growth on the surface of teeth is crucial to the
formation of dental plaque and dental cavities. Streptococcus mutans in particular adheres to teeth
and utilizes dietary sucrose to synthesize extracellular insoluble glucans that can serve as scaffolding
for other microbes to colonize (Koo et al., 2013). Tooth decay ensues when S. mutans and other
microbes residing within the plaque biofilm produce acids that erode enamel. Along with the
exopolysaccharides glucan and dextran, the composition of S. mutans biofilms has been described
in detail (Klein et al., 2015), and contains adhesin proteins and extracellular DNA (eDNA) (Liao
et al., 2014). Biofilm three-dimensional structure is established when microcolonies of S. mutans
attached to a substrate multiply and then grow vertically, connecting with one another via the
extracellular polymers. Throughout the biofilm matrix, water channels transport nutrients and
signaling molecules to the cells (Donlan and Costerton, 2002). This 3D architecture facilitates
creation of low-pH microhabitats for oral microbes (Xiao et al., 2012). The presence of and
interplay between these molecular polymers, and the water channels, contribute to the stability
Frontiers in Microbiology | www.frontiersin.org 1 March 2017 | Volume 8 | Article 488
fmicb-08-00488 March 22, 2017 Time: 16:29 # 2
Ansari et al. Peptide Anti-Biofilm Activity against S. mutans
of the network of the biofilm matrix that supports the cells.
Interfering with S. mutans biofilm architecture may help prevent
formation of oral biofilms that lead to dental caries.
Anti-biofilm molecules have been described with diverse
mechanisms of action, such as: inhibiting bacterial adhesion,
disrupting intercellular communication, and otherwise
dispersing or preventing the establishment of biofilms (Bjarnsholt
et al., 2013; Rendueles et al., 2013; de la Fuente-Núñez et al.,
2014). In contrast to antimicrobial peptides, which are important
tools to combat oral pathogens (Chen et al., 2014; Ding et al.,
2014), some anti-biofilm agents do not directly kill bacteria,
but instead interfere with their biofilm-forming capacity.
Without the protective assemblage of the biofilm matrix,
bacterial cells are more readily accessible and susceptible to
antibiotics or disinfectants (Basak et al., 2013; Otter et al., 2015).
Since early biofilm establishment by oral streptococci often
precedes the attachment of other oral pathogens, inhibiting
these biofilms may help prevent further disease (Xiao and Koo,
2010). Anti-biofilm molecules with activity against S. mutans
and other oral streptococci include natural products such as
alpha-mangostin (Thi et al., 2014), salivary mucin glycoprotein
(Frenkel and Ribbeck, 2015), polysaccharide-degrading enzymes
(Otsuka et al., 2015), MPC-polymers (Hirota et al., 2011),
and small molecules that antagonize glucosyltransferases
(Chen et al., 2015).
Synthetic peptides represent a promising class of anti-
biofilm molecules, with activity against a variety of pathogens
(Di Luca et al., 2015; Cardoso et al., 2016; de la Fuente-
Núñez et al., 2016; Pletzer and Hancock, 2016). A cationic
synthetic peptide, called P1, derived from the Ixodes tick
antifreeze glycoprotein (IAFGP), demonstrates potent anti-
biofilm activity against Staphylococcus aureus, and confers an
antivirulence effect in a catheter infection mouse model (Heisig
et al., 2014). Given its strong effect against S. aureus, we
investigated the ability of peptide P1 to combat Streptococcus
mutans biofilm formation. Antivirulence peptide P1 (distinct
from the streptococcal adhesin protein that is called P1 or
AgI/PAc) is a 24-amino acid synthetic peptide designed with
repeated motifs found in the full IAFGP antifreeze glycoprotein
sequence (Heisig et al., 2014) (Supplementary Table 2). Its
sequence contains a positively charged N-terminal “PARKAR”
motif followed by six “Ala-Ala-Thr” (AAT) repeats, a tripeptide
repeat that is also characteristic of fish antifreeze glycoproteins
(Neelakanta et al., 2010; Nagel et al., 2012). Biofilm assays
were conducted in vitro in tissue culture plates and on glass
coverslips, and S. mutans biofilms were also tested on saliva-
coated hydroxyapatite (sHA) discs, which mimic the tooth
surface. Here we demonstrate that peptide P1 disturbs the biofilm
architecture in S. mutans, resulting in a drastic reduction of
attached biofilm biomass.
MATERIALS AND METHODS
Peptide Synthesis and Bacterial Cultures
Peptides were synthesized by Genscript (Piscataway Township,
NJ, USA) at >80% purity. Peptides P1 and sP1 matched
previously published amino acid sequences (Heisig et al.,
2014) and the alternative peptide sequences P0, P1–4, P1–
7, and P17 were designed as variations of the P1 sequence
(Figure 6 and Supplementary Table 2). Lyophilized peptides
were diluted in phosphate-buffered saline (PBS) to a stock
concentration of 1 mg/ml and used immediately or frozen at
−20◦C in 100 µl aliquots. Streptococci bacteria (Streptococcus
mutans ATCC 25175, Streptococcus oralis ATCC 9811, and
Streptococcus salivarius ATCC 13419), Gram-negative bacteria
(Alcaligenes faecalis ATCC 8750, Enterobacter cloacae ATCC
23355, and Salmonella typhimurium ATCC 29629), and Gram-
positive bacterial strains (Abraham et al., 2017) were obtained
from Yale University or Presque Isle Cultures (Erie, PA, USA).
Bacterial cultures were maintained on Brain Heart Infusion
(BHI) agar or broth (for streptococci), and Tryptic Soy agar or
broth (TSA, TSB).
Biofilm Microplate Assay and Viability
Assay
Biofilm assays were performed as previously described (Merritt
et al., 2011). Overnight cultures of S. mutans grown in BHI
medium added to BHI+1% sucrose (BHI-S) at a concentration
of 3–5 × 106 cfu/ml [by either a 1:100 dilution or normalizing
to an optical density at 600 nm (OD600) of 0.015]. The bacterial
suspension was inoculated into quadruplicate wells of a 96-well
tissue culture plate and P1 peptide or control sP1 peptide was
added at a final concentration of 0.1 mg/ml (46 µM). Bacteria
were incubated overnight at 37◦C with a CO2 GasPak (BD,
Franklin Lakes, NJ, USA). Crystal violet staining of biofilm plates
was performed using standard protocols (Merritt et al., 2011),
as follows: Non-adherent cells were washed off by submerging
the plate in water, and adherent cells were stained with 0.1%
crystal violet, washed twice with water, dried, and resuspended in
33% acetic acid for 10 min. The absorbance of the resuspended
solution was measured at 590 nm on a BioTek microplate
reader. For the other Gram-negative and Gram-positive bacterial
strains, the assay was identical except that the 96-well plates
were incubated aerobically, and the biofilm culture media was
TSB + 1% glucose for Gram-negatives, and BHI+1% glucose for
Gram-positives.
To assess the bactericidal activity of P1 against S. mutans,
overnight cultures of S. mutans were inoculated into 12-well or
24-well plates at a 1:100 dilution in BHI-S containing 0.1 mg/ml
of P1 peptide, control sP1 peptide, or no peptide, and incubated
overnight at 37◦C with a CO2 GasPak. The S. mutans cells were
collected in two ways: first, as a total (combined) sample, pooling
all cells in both the supernatant (planktonic) and biofilm fraction;
secondly, the supernatant (non-adherent) and biofilm fractions
were separated and processed separately. For the combined
sample, the attached biofilm cells were scraped off the bottom
using a sterile 1.8 cm cell scraper, resuspended, and the entire
contents of the well were transferred to a microcentrifuge tube.
An additional 500 µl of PBS was added to the well and re-scraped
to pick up any remaining adherent cells. For the separated
fractions, the supernatant (containing planktonic bacteria) was
pipetted off and transferred to a 1.5 ml tube, then 500 µl of PBS
was added gently to the well to rinse off non-adherent cells, and
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transferred to the same “supernatant” tube. The biofilm cells were
resuspended into 1 ml of PBS using a cell scraper, transferred to
a new tube, and an additional 500 µl of PBS was added to the
well and re-scraped to collect any remaining adherent cells. All
samples (total, supernatant, or biofilm) resuspended in a total
volume of 1.5 ml each, were briefly sonicated to break up cell
clumps (10 pulses at 30–40% duty cycle), then serially diluted
in PBS to 10−7, spread-plated on BHI agar, and incubated for
48–72 h at 37◦C with a CO2 GasPak. After counting colonies, the
number of colony-forming units (cfu/ml) was calculated for each
sample.
Saliva-Coated Hydroxyapatite (sHA) Disc
Experiments
The sHA disc procedure was carried out according to published
protocols (Lemos et al., 2010). We prepared authors’ own clarified
saliva for each experiment as follows: ∼10 mL of saliva was
collected in a Falcon tube, stored on ice, and mixed with an equal
volume of Adsorption Buffer (AB; 50 mM KCl, 1 mM potassium
phosphate, 1 mM CaCl2, 0.1 mM MgCl2, pH 6.5), followed by
the addition of 10 µl of 0.1 M phenylmethyl-sulfonyl fluoride
(PMSF). The mixture was centrifuged at 5500 × g for 10 min
at 4◦C. The supernatant (containing clarified whole saliva) was
pipetted off carefully and filtered through a 0.22 µm PES low
protein-binding filter (Steriflip, EMD Millipore, Billerica, MA,
USA) and used immediately or stored at 4◦C. Sterile 5-mm
diameter hydroxyapatite (HA) discs (3D Biotek, Bridgewater,
NJ, USA) were aseptically placed into a sterile 15 ml tube
containing 5–10 mL of clarified saliva and rotated at 37◦C for
1 h to coat discs with saliva. The sHA discs were then placed
vertically in custom-made wire holders in pre-seeded wells of
the 96-well culture plates. Triplicate wells were inoculated with
a final volume of 200 µl of Streptococcus mutans in BHI-S
(diluted to an OD 600 nm of 0.015), with either P1 or control
sP1 peptides at 0.1 mg/ml. The plate was incubated at 37◦C
with a CO2 GasPak for 24 h. Discs were removed with sterile
forceps, dip-washed three times in 0.89% NaCl, and placed in
glass tubes containing 1 mL of 0.89% NaCl. The glass tubes
were distributed in a custom Styrofoam rack and subjected to
a 10-min ultrasonic bath. Following the ultrasonic bath, the
detached cell suspension was transferred into microfuge tubes
and sonicated (2x 5 pulses, on ice) to break up clumps of cells.
Cells were serially diluted in PBS to 10−5, then plated on BHI
agar and incubated at 37◦C with a CO2 GasPak. After 48–72 h
of incubation, S. mutans colonies were counted and cfu/disc was
calculated.
Peptide Binding Assay and Immunoblot
Analysis
Approximately 1.5 × 107 cells of S. mutans, from an overnight
culture growing in BHI, were pelleted and washed in PBS and
resuspended in 100 µL PBS. His-tagged P1 or sP1 peptides
(GenScript, Piscataway Township, NJ, USA) were added to the
cultures at 0.1 mg/mL. Bacteria-peptide mixtures were incubated
for 10 min at 37◦C. Cells were pelleted by centrifugation,
the supernatant (unbound fraction) was removed, and the
pellet-associated (bound) fraction was washed with 0.1% Triton
X-100 (Sigma–Aldrich, St. Louis, MO, USA) in PBS. The pellet
(Associated) fraction and the supernatant (unbound) fraction
were spotted directly onto a nitrocellulose membrane for
immunoblot analysis. Bacterial bound (Associated) or unbound
(Supernatant) peptide was detected using a monoclonal
His-tagged antibody (Clontech, Mountain View, CA, USA).
Cell wall bound fraction (Associated) versus unbound
(Supernatant) bacterial fractions were distinguished using
a polyclonal anti-Wheat Germ Agglutinin (WGA) (Vector
Laboratories, Burlingame, CA, USA) antibody that detects
bacterial peptidoglycan. Primary antibodies for both His and
WGA were used at a 1:2000 dilution. Appropriate IR-conjugated
LICOR secondary antibodies were used at a 1:5000 dilution and
detected using the LI-COR Odyssey system (LI-COR, Lincoln,
NE, USA). To normalize for any differences in reactivity between
P1-His and sP1-His with the anti-His antibody, we quantified
the bound signal intensity (Associated) and represented it as
a percentage of the total signal (Associated + Supernatant):
Relative Signal Intensity = [Associated (P1 or sP1) Signal][Associated+ Supernatant Signal]∗100 .
Phase Contrast and Fluorescent
Microscopy
Overnight cultures of S. mutans were inoculated at a 1:100
dilution in BHI-S with 0.1 mg/ml of P1 peptide or control
sP1 peptide. Biofilms were formed either on coverslips in 6-
well plates, or directly on the surface of 12-well or 24-well
tissue culture plates (Corning, Corning, NY, USA). Bacteria were
incubated overnight at 37◦C in containers with a CO2 GasPak.
Biofilm cultures and peptides in solution in tissue culture plates
were viewed with phase contrast microscopy using a Zeiss Axio
Vert.A1 microscope. For eDNA staining, a Miami Orange DNA-
binding fluorescent probe (Kerafast, Boston, MA, USA) was
used at a 1:200 dilution in the well, and viewed with a TRITC
fluorescent filter. Images were captured using either a mounted
camera with SPOT imaging software (SPOT Imaging, Sterling
Heights, MI, USA) or an iPhone camera (Apple, Cupertino,
CA, USA) mounted to the eyepiece of the microscope with
a MiPlatform (Scientific Device Laboratory). Scale bars were
calibrated using a stage micrometer.
Scanning Electron Microscopy (SEM)
S. mutans was inoculated at a 1:100 dilution into 500 µl of
BHI-S in a 12-well tissue culture plate, with glass coverslips
or silicon wafers aseptically placed at the bottom to allow
for biofilm formation. Peptide P1 at 0.1 mg/ml was added to
half of the samples, and the other half contained 0.1 mg/ml
control peptide sP1. After 24 h of incubation with CO2 at 37◦C,
the coverslips and wafers were gently rinsed twice in 0.12 M
phosphate buffer for 10 min. Coverslips/wafers were suspended
for 1 h in a fixative solution containing 1.5% glutaraldehyde and
1% formaldehyde in 0.12 M phosphate buffer, followed by two
rinses in 0.12 M phosphate buffer. Coverslips and wafers were
then fixed in 1% OsO4 in 0.12 M Phosphate for 30 min, followed
by a di H2O rinse. Next, the coverslips/wafers went through
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FIGURE 1 | Anti-biofilm effect of peptide P1 in microplate assay and on sHA discs. (A) Peptide P1 reduces biofilm formation by Streptococcus mutans and
oral streptococci in microplate assay. Cultures were incubated with peptide P1 and control peptide sP1 at 0.1 mg/ml final concentration. Biofilm biomass in
microplate wells was stained with crystal violet (images below graph). Results are combined from three replicate experiments, and error bars indicate standard error
of the mean. ∗∗p < 0.01, ∗∗∗∗p < 0.0001, Student’s t-test. (B) Determination of minimum biofilm inhibitory concentration of peptide P1 against S. mutans. Biofilm
inhibitory activity of P1 was measured by testing decreasing peptide concentrations in a microplate assay. Results were combined from three experiments, with
biofilm biomass normalized to a percentage of the control. (C) Viability of S. mutans in the presence of peptide P1. Total S. mutans biomass (combined planktonic
and biofilm cells from well) of cultures grown overnight in Brain Heart Infusion + 1% sucrose (BHI-S) without peptide or with 0.1 mg/ml P1 or sP1 was collected,
diluted and plated, and cfu/ml was quantified for each condition. (D) Peptide P1 reduces Streptococcus mutans biofilm formation on saliva-coated hydroxyapatite
(sHA) discs. Biofilm cfu/sHA disc showing combined results from three replicate experiments (total n = 9 discs/treatment). Peptide P1 and control peptide sP1 were
used at 0.1 mg/ml final concentration. Error bars show standard error of the mean. ∗p < 0.05, using Student’s t-test. (E) Custom-made wire holder holding the
hydroxyapatite disc vertically in the well of a 96-well plate.
an ethanol dehydration process, suspended in the following
concentrations of ethanol for 20 min each: 30, 50, 70, 95, 100%
ethanol. Following the 100% ethanol, samples were moved to
the critical point dryer in liquid CO2. After critical point drying,
the coverslips/wafers were sputter coated with gold palladium
in argon gas. Biofilm samples were imaged at the UConn
BEML facility using an FEI Nova NanoSEM 450. Images were
photographed at magnifications ranging from 500× to 50,000×,
and the 3084× magnification was selected for bacterial chain
length measurement. Twenty additional images from the P1 and
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FIGURE 2 | Immunoblot assay of S. mutans binding to His-P1 peptide or His-sP1 control peptide. (A) Peptides were detected using a monoclonal
His-tagged antibody (α-His). Cell wall bound fraction (Associated) versus unbound (Supernatant) bacterial fractions were distinguished by using a polyclonal
anti-Wheat Germ Agglutinin antibody (α-WGA). (B) Quantification of bound antiserum of His-tagged peptide in the cell-associated fraction. The Relative Signal
Intensity is the signal of “associated” fraction as a percentage of total signal detected for each peptide [associated/(supernatant + associated)]∗(100). Lower dotted
line indicates the limit of detection by the LICOR Odyssey system. ∗p < 0.05, using Student’s t-test.
FIGURE 3 | Peptide P1 activity against biofilms of Gram-negative
bacteria. Biofilm biomass in microplate wells was stained with crystal violet
(images below graph). Results are combined from three replicate experiments
with cultures grown in TSB + 1% glucose, using peptides P1 and sP1 at
0.1 mg/ml final concentration. Error bars indicate standard error of the mean.
control sP1 biofilms were taken at 3084×, and two representative
images per treatment were used to estimate streptococcal chain
length. Chains of cells with a clear beginning and end (30 chains
per treatment group) were randomly selected and chain length
was measured with ImageJ software (Schneider et al., 2012).
Fourier Transform Infrared (FTIR)
Spectroscopy
Synthetic peptides P1, P17, and sP1 were diluted to a
concentration of 1 and 0.1 mg/ml in PBS. Aliquots of 8 µl per
sample were dried as thin films directly on the ATR surface
of a Bruker Alpha Platinum-ATR FTIR (Bruker Daltonics,
Billerica, MA, USA). To scan for absorption peaks indicating
the presence of β-sheets, spectra were recorded in the range of
1800–1500 cm−1 at a resolution of 2 cm−1, with 50 scans per
sample.
Statistical Analysis
Experiments were repeated independently at least three
times, and one representative experiment or pooled data are
shown. Data were analyzed using GraphPad Prism version
6.0 software (GraphPad Software, Inc., La Jolla, CA, USA).
Statistical significance was determined using Students t-test
with Welch’s correction (when comparing two groups) or One-
Way ANOVA with Dunnett’s or Sidak’s multiple comparison
post-test.
RESULTS
Antivirulence Peptide P1 Reduces
S. mutans Biofilm in Microplates and on
sHA Discs
The biofilm microplate assay using crystal violet staining is
a rapid and convenient test for static biofilm formation.
We cultured Streptococcus mutans cultures in BHI medium
containing 1% sucrose, along with peptide P1 or a randomized
scrambled peptide, sP1, a previously published negative control
(Heisig et al., 2014). Peptides were used at a final concentration
of 0.1 mg/ml (46 µM). As shown in Figure 1, when co-incubated
with peptide P1 overnight, the biofilm biomass of Streptococcus
mutans was reduced by approximately 80% compared to the
control biofilms (sP1 peptide or no peptide) (Figure 1A).
Likewise, incubation with P1 under the same conditions also
reduced biofilm formation by two other oral streptococci,
Streptococcus oralis and Streptococcus salivarius (Figure 1A).
To determine the minimum effective concentration for biofilm
inhibition of S. mutans, we tested decreasing concentrations
of peptide P1. Significant anti-biofilm activity was observed
at concentrations down to 25 µg/ml (Figure 1B), however,
0.1 mg/ml gave consistent results and was used for all other
experiments. Despite inhibiting biofilm formation, peptide P1
was not bactericidal against S. mutans, similar to the effect
on S. aureus (Heisig et al., 2014). Viability assays revealed a
similar number of total colony-forming units present in control
cultures and cultures incubated with P1, after dilution and
plating of the entire contents of the tissue culture well (biofilm
and non-adherent cells) (Figure 1C). As expected, when cells
from the biofilm and non-adherent (supernatant) fractions were
processed and quantified separately, there were ∼80% fewer
cfu/ml in the biofilm-associated fraction of the P1-incubated
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S. mutans cultures compared to controls, and more cfu/ml
in the non-adherent (supernatant) fraction (Supplementary
Figure 1).
To investigate the effect of peptide P1 on S. mutans biofilms
in an in vitro tooth model, we prepared sHA discs, an
established model that mimics tooth enamel coated with a
salivary pellicle (Koo et al., 2010). The sHA discs were coated
with clarified saliva using a standard method (Lemos et al.,
2010) and incubated vertically for 24 h in handmade wire
holders in 96-well plates (Figure 1E) with S. mutans in BHI-
S with peptide P1 or sP1. After incubation, attached biofilm
bacteria were collected from the discs (by washing to remove
loosely attached bacteria, then placed in tubes in an ultrasonic
bath to detach biofilm bacteria from the discs). The detached
biofilm bacterial suspension was sonicated to break up clumps
of cells before plating onto BHI agar. When S. mutans was
cultivated on the discs in the presence of P1, we observed a
70% decrease in the number of biofilm colony-forming units
(cfu) per disc (7.7 × 106 cfu/disc) compared to the sP1 control
(2.8 × 107 cfu/disc) (Figure 1D). We did not observe a
significant difference in 48-h biofilms of S. mutans (data not
shown).
Peptide Binding to S. mutans and Biofilm
Inhibition of Other Bacteria
The full-length IAFGP protein, from which P1 was designed, was
previously shown to bind to the cell surfaces of a range of bacteria,
including both Gram-positive and Gram-negative species (Heisig
et al., 2014). Direct binding between both IAFGP and peptide P1
and cell wall peptidoglycan of S. aureus and Enterococcus faecalis
was recently discovered (Abraham et al., 2017). To establish
whether peptide P1 can bind to S. mutans cells, we performed
an immunoblot assay with His-tagged peptide P1 or sP1. The
His-tagged peptides were incubated with a culture of S. mutans,
then the cells were spun down, washed, and the cell-associated
and unbound fractions were probed with anti-His antibody. As
shown in Figure 2, there was strong binding detected between
His-P1 peptide with the cell-associated S. mutans fraction (anti-
His, “Associated”), while only a trace amount of His-sP1 control
peptide was detected bound to cells.
Since P1 peptide binds to S. mutans, and IAFGP binds
to a range of bacteria (Heisig et al., 2014), we wished to
investigate the anti-biofilm effect of P1 against other bacteria.
Recently, Abraham et al. (2017) reported that P1 had strong anti-
biofilm activity against biofilms of Gram-positive species, and no
effect on Escherichia coli and P. aeruginosa biofilm formation
(Abraham et al., 2017). We tested the peptide against three
additional biofilm-forming Gram-negative strains, A. faecalis,
Enterobacter cloacae, and Salmonella typhimurium, and did not
detect any statistically significant biofilm inhibition (Figure 3).
Supplementary Table 1 summarizes the findings from both
studies on peptide P1 against the Gram-positive and Gram-
negative bacteria tested thus far. Biofilms of Gram-positive
species were reduced by 35–80%, and statistically significant
reduction of biofilm by peptide P1 could be detected at
concentrations as low as 5 µg/ml against S. oralis, and 10 µg/ml
against S. aureus (Supplementary Table 1).
P1-Treated Biofilms have Disconnected
Exopolymeric Matrix and Shorter Chains
of Streptococci.
When S. mutans biofilms were allowed to form in the wells of
12- or 24-well tissue culture plates, cultures in the presence of
peptide P1 exhibited large aggregates of cells and exopolymeric
matrix, that detached readily from the surface (Figure 4 and
Supplementary Figure 1). Control sP1-treated biofilms were
more uniform and firmly attached, with a continuous network
of cells and exopolymeric matrix material (Figure 4 and
Supplementary Figure 1). To visualize eDNA in the biofilm
matrix, we stained the total contents of the wells (adherent and
suspended) with a fluorescent DNA-binding dye, and observed
the same pattern of unevenly clumped matrix material with less
attached to the surface of the well (Figure 4D).
To further examine the altered biofilm structure of S. mutans
treated with peptide P1, we performed SEM to look for
differences in biofilm architecture and cell morphology at high
resolution. At 500× magnification, there were fewer clumps
of attached S. mutans microcolonies in the P1-treated sample
(Figure 5A). At 3084× magnification, striking differences in
streptococcal chain length were apparent between the samples,
with the control cells forming significantly longer chains that
were extensively interlinked (Figure 5B). We measured chain
lengths using ImageJ software and found that the majority
of streptococcal chains in the P1-incubated biofilm were less
than 6 µm long, while chains of cells in the control group
were more than twice as long, with most measured at 10–
16 µm (Figures 5C,D). The representative images in Figure 5B
illustrate that cells of control biofilms form a more interconnected
network, while cells incubated with P1 exist in discontinuous
clumps.
Anti-Biofilm Activity Correlates with
Peptide Sequence and Aggregation in
Solution
To explore whether altering the sequence of P1 could enhance or
eliminate its anti-biofilm activity, we designed modified peptide
sequences and tested their anti-biofilm effect on S. mutans and
S. aureus. Figure 6 lists the alternative peptide sequences with
color-coded amino acid residues. Additional details including
peptide molecular weights and net charges can be found in
Supplementary Table 2. Peptide P0 directly matches the repeated
sequence in the full length IAFGP protein (with ‘PATAAT’
instead of ‘AATAAT’). Peptides P1–4 and P1–7 have fewer (4) or
more (7) ‘AAT’ repeats, respectively, than P1. P17 is a different
randomized scrambled peptide that lacks the proline residue. As
seen in Figure 6, each peptide had similar effects against both
S. mutans and S. aureus at 0.1 mg/ml in the microplate crystal
violet assay. None of the peptides with alterations in the ‘AAT’
repeats (P0, P1–4, or P1–7) reduced biofilm formation. The only
variant peptide that showed some anti-biofilm activity was P17,
which is a scrambled version of P1 that lacks the proline residue,
and contains the three positively charged amino acids (R,R,K) at
the C-terminus. Its effect was slightly less potent than that of P1.
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FIGURE 4 | Clumping and detachment of exopolymeric matrix in the presence of P1. (A) S. mutans cultures in well of 12-well plate after overnight incubation
with peptide P1 or sP1 at 0.1 mg/ml. Detached chunks of floating matrix material are visible in P1-treated sample (no magnification). (B) Cells and exopolymeric
matrix (same samples from A) viewed through 10× objective with phase contrast microscopy. Bar = 100 µm. Cells and matrix appear dark, clear areas show lack of
biofilm attached to well. (C) Matrix clumping in wells of 24-well plate. (D) Biofilm eDNA (same samples from C) stained with fluorescent Miami Orange probe and
viewed under fluorescent light with 20× objective. Bar = 100 µm.
In addition to sharing the 24-aa length and +3 net charge at
the terminus, P1 and P17 displayed another common property.
These peptides form visible aggregates in BHI-S solution, even
without bacteria present. Figure 7 shows microscopic images of
each peptide in solution, with and without S. mutans bacteria, at
6 and 24 h of incubation. Figures 7A,C display the conspicuous
self-aggregation of peptides P1 and P17 (arrows). After the
bacterial biofilm forms, the wells treated with P1 and P17 display
floating chunks of matrix material that appear to associate
directly with the aggregated peptide.
The ability to self-aggregate indicates that P1 and P17 may
have different secondary and tertiary structure than the other
peptides, depending on the relative locations of proline and the
charged and uncharged amino acids in each sequence (Figure 6).
We used Fourier transform infrared spectroscopy (FTIR) to
assess the secondary structure of these two peptides compared
to the negative control, sP1 (Haris and Chapman, 1995). The
assembly of P1 and P17 peptide monomers into higher order
β-sheet structures were confirmed by the presence of a peaks at
1621 and 1695 cm−1 (Figure 8), characteristic for antiparallel
β-sheet formation (Cerf et al., 2009).
DISCUSSION
The synthetic peptide P1, designed from a tick antivirulence
protein, strongly reduced biofilm formation by the oral pathogen
Streptococcus mutans in an in vitro microplate assay and the sHA
disc tooth model. Biofilm structure was drastically disrupted in
S. mutans, with P1-incubated biofilms displaying sparse, irregular
attachment, and chunks of matrix and cells that detached into
the culture medium. In addition, the chains of streptococcal
cells remaining attached in P1-treated biofilms were shorter
and less interconnected than control cell chains, suggestive of a
disturbance in the 3D structure of the biofilm. Peptide P1 formed
aggregates in solution, and alternative peptides containing
variations of the repeated ‘AAT’ sequences did not possess anti-
biofilm activity, with the exception of P17, a peptide that also
aggregated and formed similar secondary structure to P1.
Combining this evidence with the direct binding observed
between P1 and S. mutans cells, we propose a model in which
peptide P1 binds to the bacterial surface and interferes with
the proper secretion and/or intermolecular interaction of key
extracellular polymers in the biofilm matrix, preventing strong
attachment to the surface and connection between microcolonies
in the biofilm (Koo et al., 2010). In biofilms of Gram-positive
bacteria, interactions between exopolysaccharide (acidic, basic, or
neutral), proteins, and the negatively charged eDNA or teichoic
acids dictate the stability of the exopolymeric matrix (Otto, 2014).
In S. mutans, eDNA plays an important role in maintaining
the mechanical stability of biofilms (Liao et al., 2014), and
interactions between eDNA in the biofilm matrix and the cation
calcium (Ca2+) were shown to enhance bacterial aggregation
and biofilm stability in several species (Das et al., 2014). As a
positively charged peptide, P1 may affect interactions between the
eDNA and exopolysaccharides, perturbing the typical bonding by
altering the net charge at the surface of cells. Disrupted stability
is evidenced by the floating chunks of cells and matrix that are
readily washed away, rather than firmly attached to the substrate
as intact biofilm.
The binding of peptide P1 at the cell surface may also interfere
with the secretion and cell wall attachment of components
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FIGURE 5 | Scanning electron microscopy of S. mutans biofilm. (A) Reduced adherent material in biofilms formed in the presence of 0.1 mg/ml peptide P1;
final magnification 500×, bar = 100 µm. (B) Biofilms in P1-treated sample display shorter streptococcal chain lengths; final magnification 3084×, bar = 10 µm.
(C) Average streptococcal chain length under each treatment, measured with ImageJ software. ∗∗∗∗p < 0.0001, Student’s t-test. (D) Distribution of streptococcal
chain lengths under each treatment.
of the biofilm exopolymeric matrix. Antivirulence P1 peptide
has recently been shown to bind to the D-ala residue of the
pentapeptide of S. aureus peptidoglycan (Abraham et al., 2017).
Since S. mutans shares the same D-ala residue in its peptidoglycan
pentapeptide, this could potentially be the location of binding
between P1 and the cell surface of S. mutans. Microscopic
evidence (fragmented matrix and shorter chain length) suggests
possible defects in cell envelope processing, which could be
a result of P1 altering the activity of peptidoglycan-binding
enzymes such as autolysin or sortase. The sortase enzyme SrtA,
which covalently links LPxTG motif-containing proteins to the
cell wall, is critical for biofilm formation in S. mutans (Lévesque
et al., 2005). SrtA governs the appropriate cell surface localization
of biofilm adhesion proteins (Oli et al., 2012), and plays a role
in regulating eDNA in S. mutans biofilms (Liao et al., 2014).
Glucosyltransferase enzymes secreted by S. mutans are important
for early attachment and glucan synthesis (Koo et al., 2010), and
their activity might be impacted by cell surface-bound peptide
P1. The mode of anti-biofilm activity by P1, with effects against
various Gram-positive biofilms (Supplementary Table 1), likely
differs depending on the composition of the exopolymeric matrix
and the key steps in biofilm maturation. However, the absence of
P1 anti-biofilm activity against Gram-negative bacteria observed
in this study (Figure 5), and by Abraham et al. (2017) against
E. coli and P. aeruginosa (Supplementary Table 1) implies that
P1 may interfere with conserved elements of the peptidoglycan,
protein secretion and/or cell surface remodeling processes shared
by certain lineages of Gram-positive bacteria.
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FIGURE 6 | Effect of alternative peptide sequences on biofilm formation. (A) Biofilm biomass of S. mutans and S. aureus, with results combined from three
replicate experiments. All peptides were used at 0.1 mg/ml final concentration. Error bars indicate standard error of the mean. ∗∗p < 0.01, ∗∗∗p < 0.001,
∗∗∗∗p < 0.0001. (B) Amino acid sequences of synthetic peptides with color-coded amino acid properties.
We propose that the peptide’s secondary structure and self-
aggregation are critical to its activity, because the anti-biofilm
effect was lost with shorter or longer versions of P1 (peptides
P1–4 and P1–7), or peptides lacking a positive net charge at one
terminus (peptides sP1 and P0) (Figure 6 and Supplementary
Table 2). The strongest anti-biofilm effect was correlated
with visible peptide aggregation (Figure 7) and formation of
antiparallel β-sheets (Figure 8). Antiparallel β-sheets contribute
to the quaternary structure of amyloid fibrils (Cerf et al., 2009),
and functional amyloid proteins are produced by many bacteria
to perform different cellular functions (Blanco et al., 2012).
Amyloid structures are now recognized for playing key roles in
stabilizing the exopolysaccharide matrix of biofilms of bacteria
(Taglialegna et al., 2016a), including S. mutans (Oli et al., 2012)
and S. aureus (Taglialegna et al., 2016b). In S. mutans, a major
constituent of the S. mutans biofilm matrix was shown to be an
amyloid-forming protein (Oli et al., 2012). This Ala-rich protein,
known as “antigen I/II, PAc, or P1” (not to be confused with
the synthetic peptide P1 used in this study), along with other
cell-surface-localized amyloidogenic proteins, are important for
biofilm stability (Oli et al., 2012; Besingi et al., 2017). The Ala-
rich, β-sheet forming properties of the synthetic P1 peptide
may interfere with native amyloid-forming proteins. Aggregation
and cell surface binding by P1 impede critical intermolecular
interactions needed for proper S. mutans biofilm architecture,
negatively impacting biofilm stability. In silico analyses of
antimicrobial peptide sequences suggest that aggregation-prone
regions are hotspots for the evolution of antimicrobial activity,
when cationization in these regions results in amphipathic helical
peptides (Torrent et al., 2011). A compendium of biofilm-active
antimicrobial peptides, with their effects on medically relevant
species, can be found in the open-access “BaAMPs” database (Di
Luca et al., 2015). Amino acid composition analysis of peptides
from this database revealed that biofilm inhibitory peptides
preferentially contained positively charged residues (Arg and Lys)
and that dipeptides such as “RK” were enriched in these peptides
(Gupta et al., 2016), suggesting the importance of the PARKAR
motif in peptide P1. A broad-spectrum cationic synthetic peptide,
Peptide 1018, which inhibits biofilms by blocking the bacterial
signaling molecule (p)ppGpp (de la Fuente-Núñez et al., 2014),
was found to be effective in reducing multispecies oral biofilms
(Wang et al., 2015).
Since biofilm formation is highly dependent on environmental
conditions and on the surface properties such as charge and
hydrophobicity of the material (Song et al., 2015), peptide P1
may be suitable for different formulations than existing anti-
biofilm molecules. Conclusions from this work can inform future
rational design of synthetic anti-biofilm peptides. In addition
to future application as an anti-biofilm catheter coating against
S. aureus infection (Heisig et al., 2014), it has potential to be used
against oral biofilms on teeth or dental implant surfaces, alone
or in combination with an antimicrobial such as chlorhexidine.
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FIGURE 7 | Aggregation of peptides in solution. Images were taken with phase contrast microscopy through the bottom of a 24-well tissue culture plate. All
peptides were added at 0.1 mg/ml final concentration in BHI+1% sucrose (BHI-S). (A) Peptides in solution after 6 h incubation; bar = 50 µm. (B) Peptides in solution
after 24 h incubation; bar = 100 µm. (C) Peptides in solution with S. mutans biofilm after 6 h incubation; bar = 50 µm. (D) Peptides in solution with S. mutans biofilm
after 24 h incubation; bar = 100 µm. Arrow = visible aggregated peptide.
FIGURE 8 | Secondary structure of peptides in solution using FTIR. Fourier transform infrared spectroscopy (FTIR) spectra of peptides P1, P17, and negative
control sP1 at 1 mg/ml, with peaks at 1621 cm−1 indicative of β-sheet formation.
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The synthetic peptide P1 is a promising candidate for further
development as an anti-biofilm agent against streptococci or
other Gram-positive pathogens.
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